In vivo and in vitro Evaluation of in situ Gel Formulation of Pemirolast Potassium in Allergic Conjunctivitis.
Shen T, Yang Z.
Drug Des Devel Ther · research-article; journal article · DOI 10.2147/dddt.s308448 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för pemirolast potassium. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
9 träffarSuppressive activity of pemirolast potassium, an antiallergic drug, on glomerulonephritis. Studies in glomerulonephritis model rats and in patients with chronic glomerulonephritis concurrently affected by allergic rhinitis.
Gohda T, Ra C, Hamada C, Tsuge T, Kawachi H, Tomino Y.
Arzneimittelforschung · research support, non-u.s. gov't; journal article · DOI 10.1055/s-0031-1296461Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis.
Miyake-Kashima M, Takano Y, Tanaka M, Satake Y, Kawakita T, Dogru M, Asano-Kato N, Fukagawa K, Fujishima H.
Jpn J Ophthalmol · controlled clinical trial; comparative study; clinical trial; journal article · DOI 10.1007/s10384-004-0127-2A comparative trial of the safety and efficacy of 0.1 percent pemirolast potassium ophthalmic solution dosed twice or four times a day in patients with seasonal allergic conjunctivitis.
Gous P, Ropo A.
J Ocul Pharmacol Ther · comparative study; clinical trial; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1089/108076804773710812Preventive effect of an antiallergic drug, pemirolast potassium, on restenosis after stent placement: quantitative coronary angiography and intravascular ultrasound studies.
Ohsawa H, Noike H, Kanai M, Hitsumoto T, Aoyagi K, Sakurai T, Sugiyama Y, Yoshinaga K, Kaku M, Matsumoto J, Iizuka T, Shimizu K, Takahashi M, Tomaru T, Sakuragawa H, Tokuhiro K.
J Cardiol · journal articlePemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies.
Abelson MB, Berdy GJ, Mundorf T, Amdahl LD, Graves AL, Pemirolast study group.
J Ocul Pharmacol Ther · clinical trial, phase iii; clinical trial; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1089/10807680260362759[Preventive mechanisms and effects of pemirolast potassium on restenosis after percutaneous transluminal coronary angioplasty: serial coronary angiography and intravascular ultrasound studies].
Yoshinuma M.
J Cardiol · clinical trial; journal article; english abstractPreventive effects of an antiallergic drug, pemirolast potassium, on restenosis after percutaneous transluminal coronary angioplasty.
Ohsawa H, Noike H, Kanai M, Yoshinuma M, Mineoka K, Hitsumoto T, Aoyagi K, Sakurai T, Sato S, Uchi T, Kawamura K, Tokuhiro K, Uchida Y, Tomioka H.
Am Heart J · clinical trial; randomized controlled trial; journal article · DOI 10.1016/s0002-8703(98)70167-x[Effects of antiallergic drug, pemirolast potassium on phospholipase D activation in antigen-stimulated rat basophilic leukemia (RBL-2H3) cells].
Nakamura Y, Nakashima S, Fujimiya H, Kumada T, Ojio K, Miyata H, Nozawa Y.
Arerugi · journal article; english abstract